These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 9704732)

  • 1. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
    J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.
    Olivieri A; Santini G; Patti C; Chisesi T; De Souza C; Rubagotti A; Aversa S; Billio A; Porcellini A; Candela M; Centurioni R; Congiu AM; Brunori M; Nati S; Spriano M; Vimercati R; Marino G; Contu A; Tedeschi L; Majolino I; Crugnola M; Sertoli MR;
    Ann Oncol; 2005 Dec; 16(12):1941-8. PubMed ID: 16157621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
    Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
    Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
    Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
    Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
    Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
    Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
    J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
    Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
    J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL
    N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.
    Baldissera RC; Nucci M; Vigorito AC; Maiolino A; Simões BP; Lorand-Metze I; Aranha FJ; Miranda EC; Pagnano KB; Ruiz MA; Moraes AA; De Souza CA
    Acta Haematol; 2006; 115(1-2):15-21. PubMed ID: 16424644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
    Philip T; Chauvin F; Bron D; Guglielmi C; Hagenbeek A; Coiffier B; Gisselbrecht C; Kluin Nelemans JC; Somers R; Misset JC
    Ann Oncol; 1991 Jan; 2 Suppl 1():57-64. PubMed ID: 2043500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
    Freedman AS; Takvorian T; Neuberg D; Mauch P; Rabinowe SN; Anderson KC; Soiffer RJ; Spector N; Grossbard M; Robertson MJ
    J Clin Oncol; 1993 May; 11(5):931-6. PubMed ID: 8487057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
    Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
    J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
    Wu GQ
    Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):47-51. PubMed ID: 7687533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.